We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVSN
RNS Number : 4384O
Verseon Corporation
07 November 2016
7 November 2016
Verseon Corporation
('Verseon' or the 'Company')
Appointment of Corporate Brokers
Fremont, Calif.-Verseon Corporation (AIM:VSN) is pleased to announce the appointment of Cantor Fitzgerald Europe and Mirabaud Securities LLP as its corporate brokers, with immediate effect.
Cenkos Securities acts as the Company's Nominated Adviser and Broker.
- Ends -
For further information please contact:
Verseon Corporation +1 (510) 225 9000 Arthur Shmurun / Amy Thai Cenkos Securities (NOMAD and +44 (0) 20 7397 Joint Broker) 8900 Mark Connelly / Steve Cox Cantor Fitzgerald Europe (Joint Broker) Marc Milmo / Phil Davies / Callum +44 (0) 20 7894 Butterfield 7000 Mirabaud Securities LLP (Joint Broker) Peter Krens For financial and business media +44 (0) 20 7321 enquiries, please contact: 2508 Buchanan Communications Ltd +44 (0) 20 7466 (PR Advisers) 5000 Henry Harrison-Topham / Sophie Cowles
About Verseon:
Verseon Corporation is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPUNUKRNNAARAA
(END) Dow Jones Newswires
November 07, 2016 02:00 ET (07:00 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
